David Campbell

Title: David Campbell: Innovator in Transglutaminase Inhibition

Introduction

David Campbell is a notable inventor based in La Jolla, CA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit transglutaminase 2 (TG2). With a total of 2 patents to his name, Campbell's work is paving the way for new therapeutic options.

Latest Patents

David Campbell's latest patents focus on transglutaminase 2 (TG2) inhibitors. These patents describe compounds and pharmaceutical compositions that inhibit TG2, along with methods for using these inhibitors to treat diseases or conditions that would benefit from TG2 inhibition. The innovative nature of these compounds highlights Campbell's commitment to advancing medical science.

Career Highlights

Campbell is currently associated with Sitari Pharma, Inc., where he continues to work on groundbreaking research. His expertise in the field has positioned him as a key player in the development of new therapeutic strategies.

Collaborations

Some of his notable coworkers include Justin Chapman and Thomas R Diraimondo. Their collaborative efforts contribute to the innovative environment at Sitari Pharma, Inc.

Conclusion

David Campbell's work in the field of transglutaminase inhibition represents a significant advancement in pharmaceutical research. His contributions are expected to have a lasting impact on the treatment of various diseases.